Conference Reports for NATAP

Back

42nd ICAAC Meeting   San Diego, CA, Sept 27-31, 2002     End Stage Liver Disease Leading Cause of Death in HCV/HIV Coinfected in France; 46% Had Cirrhosis; 37% had >200 Cd4s & <500 copies/ml viral load - (10/30/02)   HIV Entry Inhibitor: BMS-806 - (10/24/02)   Quality and Quantity in HIV Treatment: A Discussion of the Quad Therapy Symposium Presented at ICAAC - A Summary by Kimberly Smith MD, MPH For NATAP - (10/24/02)   Boosted PIs: differences emerging in efficacy, tolerability, lipids. - Graeme Moyle MD, MBBS, Associate Director of HIV Research, Chelsea and Westminster Hospital London, UK. - (10/24/02)   TMC-125, a new NNRTI for patients with NNRTI resistance: drug interactions with NNRTIs and protease inhibitors - (10/21/02)   Entry Inhibitors & New Test to Identify Co-receptor Use - (10/15/02)   Switch from d4T to Abacavir: changes in fat and mitochondria - (10/15/02)   Perspectives on hormonal, mitochondrial and metabolic changes - Reported by Mike Youle, MD, Royal Free Hospital, London - (10/15/02)   NRTI Sparing Regimens - (10/15/02)   ICAAC San Diego 2002: new therapy approaches; hormones and metabolics Reported by Mike Youle, MD, Royal Free Hospital, London - (10/9/02)   Lipid Analysis in Efavirenz & Nelfinavir Regimens - (10/8/02)   Switch Study in Children to Efavirenz from Protease Inhibitor - (10/8/02)   Resistance to Atazanavir - (10/7/02)   HIV Healhcare Costs Driven by CD4 Count - (10/7/02)   Hepatitis C: Can You Replace the Liver Biopsy With Less Invasive Tests - (10/7/02)   Tenofovir in the Treatment of Individuals Co-Infected with HIV and Hepatitis B Abstract - (10/7/02)   PegIntron plus Ribavirin vs Interferon plus Rinavirin in HCV/HIV Coinfected Patients: preliminary week 48 results - (10/7/02)   Kaletra + Amprenavir & Boosted Ritonavir in PI Experiened Patients - (10/7/02)   Integrase Inhibitors Advancing: S-1360 & metabolic abormalities - (10/1/02)   T-20 and T-1249 - (10/1/02)   NEAT Study: new formulation of amprenavir - (9/30/02)   FTC+Efavirenz+ddI EC Once Daily; Tenofovir & mitochondrial DNA - (9/30/02)   Substitution of Efavirenz or Nevirapine for Protease Inhibitor (80% "success") - (9/30/02)   Kaletra: 4 year follow-up - (9/30/02)   Atazanavir: The Story Unfolds with Effectiveness Comparable To Efavirenz - (9/30/02)   Hepatitis ICAAC Report 1: identifying unknown routes for HCV transmission - (9/30/02)   3TC Once Daily: equivalent to 3TC twice daily - (9/30/02)   New Entry Inhibitors In Early Development - (9/27/02)   New Discovery in HIV - (9/27/02)